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BACKGROUND: Thyroid carcinomas represent the most frequent endocrine malignancies. Recent studies were
able to distinguish malignant from benign nodules of the thyroid gland with diffusion-weighted imaging (DWI).
Although this differentiation is undoubtedly helpful, presurgical discrimination between well-differentiated and
undifferentiated carcinomas would be crucial to define the optimal treatment algorithm. Therefore, the aim of this
study was to investigate if readout-segmented multishot echo planar DWI is able to differentiate between
differentiated and undifferentiated subtypes of thyroid carcinomas. PATIENTS AND METHODS: Fourteen patients
with different types of thyroid carcinomas who received preoperative DWI were included in our study. In all
lesions, apparent diffusion coefficient (ADC)min, ADCmean, ADCmax, and D were estimated on the basis of
region of interest measurements after coregistration with T1-weighted, postcontrast images. All tumors were
resected and analyzed histopathologically. Ki-67 index, p53 synthesis, cellularity, and total and average nucleic
areas were estimated using ImageJ version 1.48. RESULTS: Analysis of variance revealed a statistically significant
difference in ADCmean values between differentiated and undifferentiated thyroid carcinomas (P = .022).
Spearman Rho calculation identified significant correlations between ADCmax and cell count (r = 0.541, P = .046)
as well as between ADCmax and total nuclei area (r = 0.605, P = .022). CONCLUSION: DWI can distinguish
between differentiated and undifferentiated thyroid carcinomas.
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Carcinomas of the thyroid gland represent the most frequent
malignancies of the endocrine system. The incidence rate of thyroid
cancer is increasing worldwide, and the disease mainly affects young
to middle-aged adults [1]. Most thyroid neoplasms are differentiated
thyroid carcinomas (DTCs) derived from follicular epithelial cells,
and among these, papillary thyroid carcinomas (PTCs) account for
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(FTCs) represent 5% to 15% of all thyroid carcinomas. Medullary
thyroid carcinomas (MTCs, arising from the parafollicular C-cells) and
undifferentiated thyroid carcinomas (UTCs) account for 5% and 2% of
all thyroid carcinomas, respectively. Patients with DTCs have excellent
survival rates, usually longer than 20 years after the initial diagnosis,
whereas MTCs and UTCs are associated with a far worse prognosis
[1,2]. Thus, therapeutic strategies for DTCs differ significantly from
poorly differentiated carcinomas like UTCs and MTCs [3].
The classical subdivision of thyroid malignancies, namely, papillary,
follicular, medullary, and undifferentiated carcinomas, is strongly
supported by molecular studies revealing the participation of specific
genes with little overlap [4–7]. Although the majority of thyroid
carcinomas can be classified using the four aforementioned
morphology-based categories, there are few carcinomas which have
features of more than one classic histopathological subtype. These tumors
reveal a distinct tumor biology and therefore a variable outcome [1].
For example, the follicular and tall cell variants of PTCs present
with a diverse outcome, yet they are both categorized as PTCs [1].
Hürthle cell carcinoma is another example of that discrepancy, as it
represents the oxyphilic subtype of FTCs, which is also associated
with a worse prognosis than standard FTCs [1].
Considering the relevance of the histopathological tumor subtypes
for optimal treatment planning, supplementary diagnostic approaches
with the ability to separate more indolent lesions which would
necessitate less radical therapies from more aggressive tumors
requiring extensive resection and adjuvant therapies are necessary.
Magnetic resonance imaging (MRI), especially diffusion-weighted
imaging (DWI), has been used as a surrogate marker of increased
mitotic activity to identify aggressive features in several tumors [8]. In
particular, different components of the apparent diffusion coefficient
(ADC) have been shown to predict increased proliferation rates and
areas of high cellularity in benign and malignant masses [9,10].
Based on the principle that DWI is able to distinguish tumors with
different cellular architecture, recent studies showed that DWI has the
potential to separate malignant and benign thyroid nodules [11–13].
The commonly used single-shot EPI sequences are prone to
susceptibility and blurring artifacts especially at 3 T and provide a
comparatively low resolution [14]. The main goal of our study is to
investigate if DWI using a readout-segmented, multishot EPI
(RESOLVE) sequence—which suffers less from the abovementioned
limitations—is able to differentiate between well-differentiated and
undifferentiated subgroups of thyroid carcinomas. Secondary goals
were to identify possible correlations of DWI biomarkers and
histopathologic data like cellularity, average and total nuclei areas, as
well as Ki-67 index and p53 expression.
Material and Methods
This study was approved by the institutional review board (Martin
Luther University ethic committee).
Patients
Overall, 20 patients with different thyroid carcinomaswere identified
in our radiological database. As only 14 patients received preoperative
MRI scans including DWI, these 14 patients were included into the
retrospective analysis. Our group’s demographics consisted of 1 woman
and 13 men with a mean age of 66 years ranging from 41 to 91 years.
Four patients (28.5%) suffered from FTCs, 4 patients (28.5%) from
PTCs, and 6 patients (43%) from UTCs.MRI
For all patients, cervical MRI was performed using a 3.0-T device
(Magnetom Skyra; Siemens, Erlangen, Germany). The imaging
protocol included the following sequences:
1. Axial T2-weighted (T2w) turbo spin echo sequence [repetition time (TR)/echo
time (TE): 4000/69, flip angle: 150°, slice thickness: 4 mm, acquisition matrix:
200 × 222, field of view: 100 mm]
2. Axial T1-weighted (T1w) turbo spin echo sequences (TR/TE: 765/9.5, flip angle:
150°, slice thickness: 5 mm, acquisition matrix: 200 × 222, field of view: 100
mm) before and after intravenous application of contrast medium (gadopentate
dimeglumine, Magnevist; Bayer Schering Pharma, Leverkusen, Germany)
3. Axial DWI (RESOLVE sequence; TR/TE: 5400/69, flip angle 180°, slice
thickness: 4 mm, acquisition matrix: 200 × 222, field of view: 100 mm) with b
values of 0, 400, and 800 s/mm2. ADC maps were generated automatically by
the implemented software package. Db800_b400 was calculated as described
previously [15].
All images were available in digital form and were analyzed by an
experienced radiologist without knowledge of the histopathological
diagnosis on a PACS workstation (Centricity PACS; GE Medical
Systems, Milwaukee, WI). Figure 1 shows conventional MRI images
(a, axial T1 without gadolinium; b, axial T1 with gadolinium; and c,
axial T2) and DWI images (d, axial b0; e, axial b400; f, axial b800;
and g, axial ADC).
The slices with the largest diameter of each tumor were selected for
DWI measurements and subsequent ADC calculation. In every case,
a polygonal region of interest as large as possible was manually drawn
on postcontrast T1w images. Every region of interest was
automatically coregistered on all other images (T2w and precontrast
T1w, b0, b400, and b800). Cystic, calcified, and necrotic areas as well
as large vessels of the lesion were avoided. In all tumors, minimal
ADC value (ADCmin), mean ADC value (ADCmean), and
maximum ADC value (ADCmax) were measured. Additionally, D
values were calculated for every tumor as described previously [15].
Histopathology and Immunohistochemistry
All thyroid carcinomas were surgically resected and histopatholog-
ically analyzed.
In every case, the proliferation index was estimated on Ki-67
antigen–stained specimens using MIB-1 monoclonal antibody
(DakoCytomation, Denmark) as reported previously [15]. Further-
more, p53 index was estimated using monoclonal antibody p57,
clone DO-7 (DakoCytomation, Denmark). Two high-power fields
(0.16 mm2 per field, ×400) were analyzed. The area with the highest
number of positive nuclei was selected. Additionally, cell density was
calculated for each tumor as average cell count per five high-power
fields (×400). Furthermore, average nucleic size and total nucleic area
were estimated using ImageJ package 1.48v (National Institute of
Health) as described previously [15].
All histopathological sections were analyzed using a research
microscope, Jenalumar, equipped with a diagnostic instruments
camera (model 4.2; Zeiss, Jena, Germany). Figure 2, a and b, shows
representative high-power fields of Ki-67– and p53-stained sections.
Statistical Analysis
Statistical analysis was performed using SPSS Version 20.
Differences between groups in DWI parameters were assessed using
one-way analysis of variance (ANOVA). Post hoc analysis was
performed using Tukey's test. Correlations between parameters of
Figure 1. Imaging and histopathological findings in a patient with undifferentiated thyroid cancer. Magnetic resonance imaging [(a) T1w axial
scan; (b) T1w axial postcontrast scan, (c) T2w axial scan] documenting a massive inhomogenous enlargement of the left thyroid lobe with
infiltration of the trachea and adjacent soft tissue.OnDWI, the lesion showsdiffusion restriction [(d)b = 0; (e)b = 400; (f)b = 800; (g) ADC].
The calculated ADC values (×10−3 mm2 s−1) are as follows:ADCmin = 0.38; ADCmean = 1.11; ADCmax = 1.95.D is 1.44× 10
−3 mm2 s−1.
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Figure 2. Histopathological findings [(a) Ki-67; (b) p53]. Ki-67
index = 32%, p53 = 66%.
Table 2. Synopsis of Histopathological Parameters of Thyroid Carcinoma
Histopathological Parameters Mean ± Standard Deviation Range
Cell count 1268.57 ± 633.97 439.00-2247.00
Total nuclei area, μm2 77,309.71 ± 47,117.75 14,649.99-163,269.00
Average nuclei area, μm2 59.14 ± 17.24 33.00-94.00
Ki-67 index, % 43.21 ± 33.11 9.00-99.00
p53 index, % 23.94 ± 31.05 0.00-94.00
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histopathology (cell count, average nucleic area, total nucleic area,
Ki-67 index, p53 synthesis) were calculated using a Spearman Rho
correlation. Significance level was set to .05.
Results
Estimated values of DWI of thyroid carcinomas (ADCmin,
ADCmean, ADCmax, and Db800_b400) are shown in Table 1.
Histopathological parameters of thyroid carcinomas are summa-
rized in Table 2.
A synopsis of the results of one-way ANOVA is given in Table 3.
Identified correlations between histopathological parameters and
DWI are displayed in Table 4.
ANOVA revealed a difference between the investigated subgroups
of thyroid carcinoma in ADCmean values which achieved statistical
significance (P = .021). A complementary box plot is shown in
Figure 3a. Tukey's test indicated that ADCmean values are different
between folliculary carcinomas and undifferentiated carcinomas (P =
.057) as well as between papillary carcinomas and undifferentiated
carcinomas (P = .031). A trend of variance between subgroups wasTable 1. Synopsis of DWI Parameters of Thyroid Carcinoma
DWI Parameters Mean ± Standard Deviation Range
ADCmin, ×10−3 mm2 s−1 0.64 ± 0.3 0.33-1.33
ADCmean, ×10−3 mm2 s−1 1.18 ± 0.36 0.83-1.97
ADCmax, ×10−3 mm2 s−1 1.91 ± 0.50 1.28-2.54
Db800_b400, ×10
−3 mm2 s−1 1.18 ± 0.61 0.36-2.22also delineable for Db800_b400, but ANOVA did not reach statistical
significance (P = .072).
Spearman Rho calculation identified statistically significant
correlations between ADCmax and cell count (r = 0.541, P = .046)
as well as between ADCmax and total nuclei area (r = 0.605, P =
.022). Trends of correlation (without achieving statistical signifi-
cance) were identified for the following pairs of parameters:
ADCmean and Ki-67 index(r = −0.508, P = .063), ADCmean and
p53 synthesis (r = 0.511, P = .062), and ADCmin and average
nuclei area (r = −0.481, P = .081).
Discussion
Our aim was to study the potential role of DWI as a biomarker using
a RESOLVE sequence at 3 T to distinguish well-differentiated
thyroid carcinoma from UTC. Further goals were to find correlations
of ADC fractions with prognostically important immunohistological
parameters like proliferation rate (Ki-67 index) and p53 synthesis as
well as cellularity and total and average nuclei area.
In the clinical (presurgical) setting, different modalities are
approached to estimate if a thyroid lesion is of rather benign or
malignant nature. Among laboratory biomarkers, exemplarily
Galectin-3 (Gal-3), several imaging modalities other than MRI, like
ultrasound and positron emission tomography–computed tomogra-
phy (PET-CT), can be used to further strengthen the suspected
diagnosis and distinguish between benign or malignant space-
occupying lesions.
Gal-3 has been investigated intensively regarding its diagnostic
importance in thyroid malignancies, as it is highly expressed in
thyroid cancer but not normal thyroid tissue and infrequently in
benign thyroid lesions [16]. Immunocytochemical studies evaluating
Gal-3 expression in needle aspiration specimens revealed that Gal-3
expression levels are significantly higher in FTC compared with
follicular adenoma [16]. Therefore, Gal-3 is a promising parameter
for presurgical evaluation of thyroid lesions with unclear dignity.
However, needle aspiration biopsy is needed to acquire tissue
specimen and therefore requires a—although minimally invasive—
surgical procedure with all its inherent risk factors.
Ultrasound (US) evaluation of the thyroid is well established in the
standard diagnostic workup and can help to indicate probable
malignancy in thyroid lesions, for example, by identification ofTable 3. Results of ANOVA Calculation of DWI Parameters from Different Histopathological
Subgroups
DWI Parameters ANOVA P value
ADCmin, ×10−3 mm2 s−1 .185
ADCmean, ×10−3 mm2 s−1 .021
ADCmax, ×10−3 mm2 s−1 .261
Db800_b400, ×10
−3 mm2 s−1 .072
Differences between groups achieving statistical significance are displayed in bold. Delineable trends
without achieving statistical significance are displayed in italics.
Table 4. Synopsis of Correlations between DWI and Histopathology
Db800_b400 ADCmin ADCmean ADCmax
Cell count r = −0.013 r = −0.204 r = 0.330 r = 0.541
P = .964 P = .483 P = .249 P = .046
Total nuclei area r = −0.013 r = −0.288 r = 0.290 r = 0.605
P = .964 P = .318 P = .314 P = .022
Average nuclei area r = −0.029 r = −0.481 r = −0.326 r = 0.185
P = .923 P = .081 P = .256 P = .527
Ki-67 index r = −0.189 r = −0.160 r = −0.508 r = −0.185
P = .517 P = .584 P = .063 P = .527
p53 index r = 0.187 r = 0.059 r = 0.511 r = 0.403
P = .522 P = .840 P = .062 P = .153
Correlations achieving statistical significance are displayed in bold. Trends of correlations are
displayed in italics.
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[17] US, being widely available, simple to perform, comparatively
cheap, and easily combinable with fine-needle aspiration biopsy, does
not involve ionizing radiation and is frequently the first choice for
evaluating thyroid nodules [18,19]. However, significant limitations
of thyroid US are high interrater variability, limited detection of
cervical metastases, and restricted evaluation of the retrosternal space
and the posterior mediastinum [20]. Despite its usefulness in the
distinction of malignant versus benign thyroid lesions [17],
differentiablility of DTC versus UTC has not been demonstrated
and may well exceed the capabilities of the method.
Hybrid imaging techniques like PET-CT combine anatomic and
metabolic imaging and have proven useful for the evaluation of
thyroid lesions [21]. Most well-differentiated thyroid carcinomas are
relatively slow growing and can be FDG negative [22]. Also, only 4%
to 7% of DTC patients present initially with distant metastases.
Therefore, the role of PET-CT in the management of patients with
DTC is primarily limited to postoperative follow-up and is not
indicated for initial staging purposes [23]. On the contrary, UTC
lesions, weather primary or metastatic, consistently show high FDG
uptake [24]. Furthermore, PET-CT is beneficial for initial staging
and early evaluation of treatment response and follow-up of UTC
patients [21]. However, hybrid imaging techniques come with few
disadvantages. Firstly, they are accompanied by a significant radiation
exposure of the patient, which cannot be justified if the lesion finally
proves not to be malignant. Secondly, they are still not available
regionwide, and thirdly, they are rather expensive diagnostic
procedures. Considering the aforementioned, hybrid imaging in the
presurgical setting is not the first choice to distinguish between
malignant and benign thyroid lesions, nor is it the best option to
differentiate between DTC and UTC.
MRI is mostly available regionwide, offers an excellent soft tissue
contrast, is less prone to interinvestigator variability than US, and is
not accompanied by radiation exposure to the patient being
examined. However, the role of MRI, especially DWI, in thyroid
cancer workup is controversial. Few studies were able to show that
DWI provides important additional information [11,25,26], whereas
other works did not find additional value in DWI [27] in the context
of thyroid cancer. However, all previous reports were based on
standard EPI sequences for DWI, whereas our study performed DWI
by means of RESOLVE DWI.
RESOLVE DWI is less liable to susceptibility artifacts, T2*
blurring, and motion-induced phase artifacts and provides higher
resolution compared with standard single-shot EPI sequences [14].Considering the small size of the thyroid (compared with
other parenchymal organs) and its close proximity to the tissue air
interface of the trachea, these properties are very important for exact
imaging of thyroid masses and certainly enhance the quality of
quantitative DWI.
In our study, ADCmean values were significantly lower in
undifferentiated carcinomas compared with follicular and papillary
carcinomas. To the best of our knowledge, this is the first study
showing the discriminability of DTC from UTC by RESOLVE
DWI. Recent studies showed the importance of DWI (using standard
EPI sequences), in particular of ADC fractions, to differentiate
between benign and malign thyroid nodules [11–13,26]. Another
recent work from Lu and colleagues showed that PTCs with
extraglandular disease manifestation had significantly lower ADC
values compared with papillary carcinomas strictly confined to the
thyroid gland and therefore concluded that DWI has a high potential
to distinguish between PTC subtypes with different tendencies of
aggressiveness [28].
Treatment of thyroid cancer is predominantly surgical [29].
Because overall mortality in thyroid cancer patients is minimal,
aggressive treatments such as total thyroidectomy or lymph node
dissection should be limited to very advanced disease stages because of
the common surgical complications like recurrent laryngeal nerve
injury or permanent hypocalcemia following removal of the
parathyroid glands [3]. Surgical options range from pure observation
(a corresponding scenario would be a young patient suffering from
microcarcinoma who is occupationally dependent on voice use, for
example, a professional vocalist), lobectomy (patient suffering from
uninodular disease limited to the thyroid), and extracapsular
thyroidectomy with preservation of the recurrent laryngeal nerve
and parathyroid glands with additional lymph node surgery
(advanced disease stage with lymph node metastases) [3,30].
Although many treatment recommendations are currently avail-
able, definitive prospective evidence to guide the thyroid surgeon is
lacking in most cases. For this reason, the optimal surgical treatments
to this increasingly common disease remain controversial [3].
Considering our results in the context of the aforementioned
works, we were able to show not only that DWI is a useful tool to
separate malign and benign thyroidal masses but that, using a
RESOLVE sequence at 3 T, it can be helpful to further distinguish
between morphologically well-differentiated carcinoma with less
aggressive tumor biology and undifferentiated carcinoma behaving
much more aggressively. This additional information about thyroid
carcinoma in the preoperative setting might aid the thyroid surgeon in
proper risk stratification and finding the best surgical treatment
algorithm for the individual patient.
Besides differences of ADCmean values of DTC and UTC, our
study revealed a trend of inverse correlation between ADCmean and
Ki-67 expression, although it did not reach statistical significance.
Ki-67 is a nuclear protein strictly associated with cell proliferation and
widely used in immunohistopathology [31]. As demonstrated
previously, increased Ki-67 expression and high cellularity in tumors
are associated with decreased ADCmean values, probably based on
decreased water diffusibility of the reduced extracellular space due to
increased proliferation of cells [10,15,32]. In addition to that, Ki-67
has been found to be a useful indicator for poor outcome in MTC
[33]. Furthermore, Ki-67 aids the discrimination of follicular
adenoma and follicular carcinoma [34]. These findings corroborate
the significance of ADCmean as an imaging biomarker for the
Figure 3. (a) ADCmean values of differentiated versus undifferentiated thyroid carcinoma. (b–f) Scatter plots graphically summarizing the
relationships between DWI parameters and (immuno)histopathological properties.
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expression underlines its relation to the proliferative activity of
tumors, which is a general hallmark of cancer [35] and important
for assessment of prognosis and therapy response in the clinical
context.
Also, a trend of positive correlation between p53 overexpression
and ADCmean was displayed in our study. p53 is one of the most
important tumor suppressors controlling cell fate mainly by
inducing growth arrest, apoptosis, and senescence [36]. Under
normal, unstressed conditions, p53 remains undetectable because ofits rapid degradation via the proteasome [36]. In case of thyroid
cancer, p53 expression is associated with a good prognosis [37–39]
and may be used as a marker to identify less aggressive cases of
thyroid cancer that may not need aggressive management [40]. As
discussed above, low ADCmean values are associated with increased
cell proliferation and therefore indicate aggressive tumor biology.
Also, increased expression of p53 shows an association with
increased ADCmean values, which further underlines the signifi-
cance of ADCmean as in vivo biomarker predicting tumor
aggressiveness.
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and cellularity in our study. Both histopathological parameters reflect
areas of increased cell density. It is well known that different ADC
fractions—in most cases, ADCmean; more seldomly, ADCmin—are
associated with increased cellular density as a consequence of reduced
extracellular space [8]. ADCmax indicates tissue areas with comparably
high water diffusibility. It is therefore somewhat unexpected that
ADCmax and cellularity as well as total nuclei area show a strong,
significant correlation. Recent studies investigated the expression of
aquaporins in thyroid carcinoma. Niu and colleagues were able to show
that normal and neoplastic thyroid tissue with follicular cell origin
expresses high levels of aquaporin 4—a protein physiologically forming
water channels in the kidneys and the central nervous system—and
therefore concluded that aquaporin 4 may play an important role for
fluid homeostasis of normal and transformed follicular thyroid cells
[41]. Complementarily, Lacroix and colleagues showed that aquaporin
7 is upregulated in a certain subtype of FTCs [42]. A correlation
between AQP4 expression and ADCmax values has been described in
other space-occupying lesions [43].We thereupon hypothesize that, as a
peculiarity, thyroid carcinoma cells of follicular cell origin, being
equipped with a comparably high set of water channels that facilitate
water diffusibility, show a clear association between increased water
diffusion in DWI in areas of increased cellularity.
This study suffers some limitations. Firstly, it is a feasibility study and
thereby only has a small number of DTC and UTC patients. A larger
cohort of patients is necessary to confirm our initial findings. Secondly,
noMTC cases are included in this study. Because of the rarity ofMTC,
no patient could be included in this investigation, and additional works
must be performed to investigate if RESOLVE DWI can be helpful to
distinguish between MTC, UTC, and DTC. As a third point, lack of
fine-needle aspiration biopsies has to be mentioned. Fine-needle
aspiration biopsies are considered a very useful diagnostic tool in thyroid
cancer workup. It would be interesting to compare our DWI data with
corresponding fine-needle aspiration biopsy results to understand
whether MRI as noninvasive tool might provide comparable (or even
superior) information to fine-needle aspiration biopsies.
Conclusion
This study shows that ADCmean values obtained from presurgical
DWI using a RESOLVE sequence at 3 T have the potential to stratify
patients based on the grade of dedifferentiation of thyroid carcinoma.
The results of our study demonstrate clearly decreased ADCmean
values in UTC compared with DTC. Therefore, ADCmean values
can aid the thyroid surgeon in the presurgical setting to preselect
optimal therapeutic strategies and inform the patient about the
probable extent of surgery and associated risks.
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